A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2058-2063

  Shankar, A G ^b   Ashley, S ^b   Atra, A ^b   Kingston, J E ^b   Mott, M ^a   Pinkerton, C R ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Bulky mediastinal disease; Primary non responses; Stage IV; VEEP

Indexed keywords

EPIRUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; PREDNISOLONE; RECURRENCE; SALVAGE THERAPY; VINCRISTINE;

EID: 0032402468     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00314-1     Document Type: Article

References (27)

1. 1. Shankar AG, Ashley S, Radford M, Barrett A, Wright D, Pinkerton CR. Does histology influence outcome in childhood Hodgkin's disease? J Clin Oncol 1997, 15, 2622-2630.
2. 2. Barrett A, Crennan E, Fracer BS, Barnes J, Martin J, Radford M. Treatment of clinical stage I Hodgkin's disease by local radiation therapy alone. A United Kingdom Children's Cancer Study Group. Cancer 1990, 66, 670-674.
3. 3. Oberlin O, Leverger G, Pacquement MA, et al. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin's Disease. The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992, 10, 1602-1608.
4. 4. Hudson M, Greenwald C, Thompson E. Efficacy and toxicity of multiagent chemotherapy and low dose involved field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993, 11, 100-108.
5. 5. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low dose involved field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol 1994, 12, 2160-2166.
6. 6. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 1982, 49, 418-422.
7. 7. Sutcliffe SB. Infertility and gonadal function in Hodgkin's disease. In Selby P, McElwain TJ, eds. Hodgkin's Disease. Oxford, U.K., Blackwells, 1987, 339-360.
8. 8. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediat Oncol 1996, 27, 74-78.
9. 9. Byrne J, Fears TR, Gall MH, et al. Early menopause in long term survival of cancer during adolescence. Am J Obst Gynaeol 1992, 166, 788-793.
10. 10. Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20 yr follow up study. J Clin Oncol 1994, 12, 312-325.
11. 11. Bonadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin. Ann Oncol 1993, 4, 359-369.
12. 12. Taylor ME, McElwain TJ, Barrett A, Peckham MJ. Etoposide as a single agent in advanced relapsed lymphomas. A phase II study. Cancer Chemother Pharmacol 1982, 7, 75-177.
13. 13. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of VEEP regimen in adult Hodgkin's Disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995, 13, 387-395.
14. 14. O'Brien MER, Pinkerton CR, Kingston J. "VEEP" in children with Hodgkin's disease - a regimen to decrease late sequelae. Br J Cancer 1992, 65, 756-760.
15. 15. Lukes RJ, Graver LF, Hall TC, Rappaport H. Reports of the Reuben P. nomenclature committee. Cancer Res 1966, 26, 1311.
16. 16. Carbone PP, Kaplan HS, Musshoff K, Smith DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971, 31, 1860-1861.
17. 17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 54, 457.
18. 18. Behrendt H, Brinkhuis M, Van Leeuwen EF. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Med Pediat Oncol 1996, 26, 244-248.
19. 19. Linch DC, Vaughn-Hudson B. The management of Hodgkin's disease and non-Hodgkin's lymphomas. In Hoffbrand AV, ed. Recent Advances in Haematology. Longman, London U.K., 1988, Vol. 5, 211-242.
20. 20. James ND, Kingston JE, Plowman PN, et al. Outcome of children with resistant and relapsed Hodgkin's disease. Br J Cancer 1992, 66, 1155-1158.
21. 21. Buzaid AC, Lippman SC, Miller TP. Salvage therapy of advanced Hodgkin's disease: critical appraisal of curative potential. Am J Med 1987, 83, 523-532.
22. 22. Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A. Third line chemotherapy for resistant Hodgkin's disease. Semin Oncol 1985, 12, 23-25.
23. 23. Crump M, Smith AM, Brand Wein J, et al. High dose etoposide and melphalan and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993, 11, 704-711.
24. 24. Vose JM, Bierman PJ, Armitage JO. Hodgkin's disease: the role of bone marrow transplantation. Semin Oncol 1990, 17, 749-757.
25. 25. Doria R, Holford T, Farber L, et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995, 13, 2016-2022.
26. 26. Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet 1993, 342, 819-820.
27. 27. Schellong G. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group. Bailliere's Clin Haematol 1996, 9, 619-634.